Sam Lanyon
Chairman at LUMOS DIAGNOSTICS HOLDINGS LIMITED
Profile
Sam Lanyon is the founder.
He founded Planet Innovation Pty Ltd.
in 2009 and holds the title of Executive Director.
Currently, Mr. Lanyon is the Executive Chairman at Lumos Diagnostics, Lumos Diagnostics Holdings Ltd., and Director at Visus Therapeutics, Inc. In the past, he worked as a Director at Waterwerx Pty Ltd.
and Zen Ecosystems.
Mr. Lanyon's education includes an undergraduate degree from the University of Melbourne.
Sam Lanyon active positions
Companies | Position | Start |
---|---|---|
LUMOS DIAGNOSTICS HOLDINGS LIMITED | Chairman | 2018-12-31 |
Visus Therapeutics, Inc.
Visus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation. | Director/Board Member | - |
Lumos Diagnostics
Lumos Diagnostics Medical SpecialtiesHealth Technology Lumos Diagnostics develops and provides diagnostic solutions. It offers assay development, reader development, and point-of-care diagnostic solutions. The company is headquartered in Carlsbad, CA. | Chairman | - |
Planet Innovation Pty Ltd.
Planet Innovation Pty Ltd. Medical SpecialtiesHealth Technology Planet Innovation Pty Ltd. is a healthtech innovation and Australian commercialization company that specializes in product development and manufacturing. The private company is based in Box Hill, AU. and has subsidiaries in the United States. It was founded in 2009 by Eduardo Vom, Sam Lanyon, Stuart Elliott, and Troy O'Callaghan, with Stuart Elliott serving as the CEO since its inception. | Founder | 2008-12-31 |
Former positions of Sam Lanyon
Companies | Position | End |
---|---|---|
Zen Ecosystems | Director/Board Member | - |
Waterwerx Pty Ltd. | Director/Board Member | - |
Training of Sam Lanyon
University of Melbourne | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
LUMOS DIAGNOSTICS HOLDINGS LIMITED | Health Technology |
Private companies | 5 |
---|---|
Waterwerx Pty Ltd. | |
Planet Innovation Pty Ltd.
Planet Innovation Pty Ltd. Medical SpecialtiesHealth Technology Planet Innovation Pty Ltd. is a healthtech innovation and Australian commercialization company that specializes in product development and manufacturing. The private company is based in Box Hill, AU. and has subsidiaries in the United States. It was founded in 2009 by Eduardo Vom, Sam Lanyon, Stuart Elliott, and Troy O'Callaghan, with Stuart Elliott serving as the CEO since its inception. | Health Technology |
Lumos Diagnostics
Lumos Diagnostics Medical SpecialtiesHealth Technology Lumos Diagnostics develops and provides diagnostic solutions. It offers assay development, reader development, and point-of-care diagnostic solutions. The company is headquartered in Carlsbad, CA. | Health Technology |
Visus Therapeutics, Inc.
Visus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Visus Therapeutics, Inc. is a clinical stage biopharmaceutical company that focuses on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is based in Seattle, WA and has subsidiaries in the United States. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. The company was founded by Benjamin Scot Bergo, Rhett M. Schiffman, and Benjamin Scot Bergo has been the CEO since incorporation. | Health Technology |
Zen Ecosystems |
- Stock Market
- Insiders
- Sam Lanyon